FSWA
NTLA icon

Financial Synergies Wealth Advisors’s Intellia Therapeutics NTLA Stock Holding History

Financial Synergies Wealth Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25
Closed -$932 – 525
2023
Q1 		$932 Buy
+25
New +$981 ﹤0.01% 382

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Financial Synergies Wealth Advisors's NTLA Position: Q2 2023 in Review

Financial Synergies Wealth Advisors sold out of Intellia Therapeutics (NTLA) in Q2 2023, closing a stake of 25 shares — an estimated $932 sold.

Financial Synergies Wealth Advisors first reported a position in NTLA in Q1 2023 and held it in 1 quarter. The position peaked at $932 in Q1 2023. 291 funds tracked by Wall St. Rank hold NTLA as of Q2 2023.

  • Financial Synergies Wealth Advisors reported no remaining Intellia Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Financial Synergies Wealth Advisors sold 25 Intellia Therapeutics shares in Q2 2023, an estimated $932.
  • Financial Synergies Wealth Advisors first reported a position in Intellia Therapeutics in Q1 2023 and held it in 1 quarter.
  • Financial Synergies Wealth Advisors's Intellia Therapeutics position peaked at $932 in Q1 2023.
  • 291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2023.

Based on Financial Synergies Wealth Advisors's 13F filing for Q2 2023, filed 4 Apr 2024.